Tsc2 is not a critical target of Akt during normal Drosophila development
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Signaling by insulin and target of rapamycin are both required for cell growth, but their interrelationships remain poorly defined. It was reported that Akt, an essential component of the insulin pathway, stimulates growth by phosphorylating and inhibiting tuberous sclerosis complex 2 (TSC2). Here we evaluate this model genetically in Drosophila by engineering Tsc2 mutants in which the Akt phosphorylation sites are changed to nonphosphorylatable or phospho-mimicking residues. Strikingly, such mutants completely rescue the lethality and cell growth defects of Tsc2 -null mutants. Taken together, our data suggest that Tsc2 is not a critical substrate of Akt in normal Drosophila development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911 · cited 1×
“…but appears to involve the tuberous sclerosis tumor suppressor proteins TSC1 and TSC2, the small GTPase Rheb, and target of rapamycin (TOR), a Ser/Thr kinase specifically inhibited by the immunosuppressant rapamycin (Garami et al. 2003; Inoki et al. 2003; Tee et al. 2003; Zhang et al. 2003).”
BackgroundManning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555 · cited 6×
“As reported in mammalian cells (Dan et al. 2002; Inoki et al. 2002; Manning et al. 2002), insulin stimulation resulted in phosphorylation of wildtype Tsc2, and this phosphorylation was abolished when S924 and T1518 were changed to nonphosphorylatable (Tsc2) or phospho-mimicking residues (Tsc2) (Fig.”
BackgroundResultInfluentialRegulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545 · cited 4×
“A long-standing question concerning insulin and TOR signaling is how the TOR-mediated nutrient signals intersect with the canonical insulin signaling pathway (Gingras et al. 2001; Shamji et al. 2003).”
BackgroundInfluentialAkt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Cited by
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Molecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,241
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
Translational control of long-lasting synaptic plasticity and memory
Costa-Mattioli, M., Sossin, W. S., Klann, E., & Sonenberg, N. (2009) · Neuron · doi:10.1016/j.neuron.2008.10.055 · Cited by 944
Regulation of mTORC1 by PI3K signaling
Dibble, C. C., & Cantley, L. C. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.06.002 · Cited by 836
Bhaskar, P. T., & Hay, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.03.020 · Cited by 798
Menon, S., Dibble, C. C., Talbott, G., Hoxhaj, G., Valvezan, A. J., Takahashi, H., Cantley, L. C., & Manning, B. D. (2014) · Cell · doi:10.1016/j.cell.2013.11.049 · Cited by 766
Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity
Hahn-Windgassen, A., Nogueira, V., Chen, C.-C., Skeen, J. E., Sonenberg, N., & Hay, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502876200 · Cited by 539
An expanding role for mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.007 · Cited by 523
Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497
PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding
Wang, L., Harris, T. E., Roth, R. A., & Lawrence, J. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702376200 · Cited by 494
The expanding TOR signaling network
Martin, D. E., & Hall, M. N. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.02.008 · Cited by 494
Molecular mechanisms of metabolic regulation by insulin in Drosophila
Teleman, A. A. (2010) · Biochemical Journal · doi:10.1042/bj20091181 · Cited by 384
Signaling by Target of Rapamycin Proteins in Cell Growth Control
Inoki, K., Ouyang, H., Li, Y., & Guan, K.-L. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.1.79-100.2005 · Cited by 330
Regulation of Tissue Growth through Nutrient Sensing
Hietakangas, V., & Cohen, S. M. (2009) · Annual Review of Genetics · doi:10.1146/annurev-genet-102108-134815 · Cited by 330
Targeting the mTOR signaling network in cancer
Chiang, G. G., & Abraham, R. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.001 · Cited by 327
Reiling, J. H., & Sabatini, D. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209889 · Cited by 311
Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase
Avruch, J., Hara, K., Lin, Y., Liu, M., Long, X., Ortiz-Vega, S., & Yonezawa, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209882 · Cited by 296
The TOR Pathway Couples Nutrition and Developmental Timing in Drosophila
Layalle, S., Arquier, N., & Léopold, P. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.08.003 · Cited by 294
TOR-dependent control of autophagy: biting the hand that feeds
Neufeld, T. P. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.005 · Cited by 256
Corradetti, M. N., Inoki, K., & Guan, K.-L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c400557200 · Cited by 237
mTOR pathway as a target in tissue hypertrophy
Lee, C.-H., Inoki, K., & Guan, K.-L. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105359 · Cited by 179
Cheah, P.-S., Prabhakar, S., Yellen, D., Beauchamp, R. L., Zhang, X., Kasamatsu, S., Bronson, R. T., Thiele, E. A., Kwiatkowski, D. J., Stemmer-Rachamimov, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb1703 · Cited by 38
Metadata
- Authors
- Dong, J., & Pan, D.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2004-10-01
- Volume
- 18
- Issue
- 20
- Pages
- 2479-2484
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W1970212288
- Cited by
- 105
- References
- 5
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.